propranolol has been researched along with Systemic Inflammatory Response Syndrome in 4 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Systemic Inflammatory Response Syndrome: A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol treatment attenuates hypermetabolism and does not cause increased incidence of infection and sepsis." | 9.12 | Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. ( Branski, LK; Finnerty, CC; Herndon, DN; Jeschke, MG; Norbury, WB, 2007) |
| "Propranolol treatment attenuates hypermetabolism and does not cause increased incidence of infection and sepsis." | 5.12 | Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. ( Branski, LK; Finnerty, CC; Herndon, DN; Jeschke, MG; Norbury, WB, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, L | 1 |
| Yu, WK | 1 |
| Lin, ZL | 1 |
| Tan, SJ | 1 |
| Bai, XW | 1 |
| Ding, K | 1 |
| Li, N | 1 |
| Rudiger, A | 1 |
| Schmitz, D | 1 |
| Wilsenack, K | 1 |
| Lendemanns, S | 1 |
| Schedlowski, M | 1 |
| Oberbeck, R | 1 |
| Jeschke, MG | 1 |
| Norbury, WB | 1 |
| Finnerty, CC | 1 |
| Branski, LK | 1 |
| Herndon, DN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A Randomized Controlled Trial[NCT03549923] | Phase 4 | 550 participants (Anticipated) | Interventional | 2018-12-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for propranolol and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Beta-block the septic heart.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Disease Models, Animal; Heart; Humans; Pro | 2010 |
1 trial available for propranolol and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children.
Topics: Adrenergic beta-Antagonists; Anabolic Agents; Burns; Child; Energy Metabolism; Female; Humans; Infla | 2007 |
2 other studies available for propranolol and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Impact of β-adrenoceptor blockade on systemic inflammation and coagulation disturbances in rats with acute traumatic coagulopathy.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Blood Coagulation Disorders; Blotting, W | 2015 |
beta-Adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis.
Topics: Adrenergic beta-Antagonists; Animals; Cell Division; Cytokines; Disease Models, Animal; Immunity, Ce | 2007 |